Abstract. B cell chronic lymphocytic leukemia (B-CLL) is known to have substantial clinical heterogeneity. There is no cure, but treatments allow for disease management. However, the wide range of clinical courses experienced by B-CLL patients makes prognosis and hence treatment a significant challenge. In an attempt to study disease progression across different patients via a unified yet flexible approach, we present a mathematical model of B-CLL with immune response, that can capture both rapid and slow disease progression. This model includes four different cell populations in the peripheral blood of humans: B-CLL cells, NK cells, cytotoxic T cells and helper T cells. We analyze existing data in the medical literature, determine ranges of values for parameters of the model, and compare our model outcomes to clinical patient data. The goal of this work is to provide a tool that may shed light on factors affecting the course of disease progression in patients. This modeling tool can serve as a foundation upon which future treatments can be based.
1. Introduction. Chronic lymphocytic leukemia (CLL, also referred to as B-CLL in the literature) is characterized by the existence of large numbers of white blood cells (B cells) in the blood, the bone marrow, the spleen and in the lymph nodes. Until recently, it was believed to be a slowly progressing disease of accumulation of abnormal B cells that were immunologically challenged, and not a disease of proliferation of these cells. It is now understood that B-CLL is a heterogeneous disease in which cells of differing functionality may continue to proliferate, with dynamics varying from patient to patient. Further details on the biology of the disease and proposed treatments can be found in several publications [1, 2, 3] .
Our goal in this paper is to capture in a mathematical model the underlying dynamics of this disease by considering the development of B-CLL cells along with three important components of the cellular immune response to B-CLL: natural killer (NK) cells, helper T cells and cytotoxic T cells. The biological literature reveals [1, 4, 5, 6, 7] that NK cells, helper T cells and cytotoxic T cells may all play a role in stemming the growth of B-CLL. In fact, potential new immunotherapies that upregulate either NK or T cell activity are being explored [4, 6, 8] . Therefore a model that includes NK cell and T cell dynamics may serve as a testbed for future immunotherapy treatments of B-CLL.
Ordinary Differential Equations (ODE) models of the type in this paper have been used to study various hematological disorders other than B-CLL [9, 10, 11, 12] . The usefulness of any such model lies in how well it emulates a range of observed phenomena of a disease. A model for B-CLL assuming competition between the cancer cells and the immune response has been described by Vitale and colleagues [13, 14] in which the entire immune response is represented by one combined population of T lymphocytes. A model of the immune response to chronic myelogenous leukemia in post-transplantation dynamics using time delays can be found in [15] where, again, one immune response is considered. However, the biological immune response to B-CLL involves several cell types. The model we present explicitly tracks the innate, helper, and specific immune responses with three separate cell populations. We examined published data for B-CLL patients to determine the appropriate functional forms in our ODE model. We compare the model to patient data in the medical literature, in particular, those provided by Messmer et al. [16] .
A significant challenge in mathematical modeling is the identification of meaningful parameter values. An important contribution of this work is the determination of parameter values that give rise to biologically realistic simulation outcomes. The parameters for this model are obtained through a careful process of mining and cross-checking the medical literature for known measurements. A sensitivity analysis reveals the variability of model outcomes with respect to the parameters, and also suggests the parameters that are most highly correlated with positive or negative disease progression. 2. Mathematical model. We use a system of four ODEs representing interacting cell populations of B-CLL and three immune responses in the peripheral blood. We include the natural killer (NK) cells which are present in the body at all times and are not specific to B-CLL, cytotoxic T cells (e.g., CD8
+ T) which respond specifically to B-CLL, and helper T cells (e.g., CD4
+ T) which are part of the specific immune response and which aid in the recruitment, proliferation and activation of cytotoxic T cells. This ODE model ignores spatial effects: the biological assumption is that the cell populations are uniformly mixed in the peripheral blood. Concentrations of B-CLL cells, NK cells, killer T cells and helper T cells (in units of cells per µliter) are represented by B, N , T and T H respectively. Time is denoted by t (days).
The system of ODEs is given by
A description of the model terms follows. B-CLL Cells: The dynamics of the B-CLL population are represented by equation (1). Only B-CLL cells, and not healthy B cells are considered. One of the goals of this model is to describe and explore the kinetics of the interactions between B-CLL cells and the immune response. It has been noted that normal B cells do not play a large role in the immune response to B-CLL [17] , and that, in a B-CLL patient, B cell levels are orders of magnitude larger than B cell levels in a healthy person. The large number of B cells and the lack of evidence for healthy B cell activity in a B-CLL patient, leads to the decision only to track B-CLL cells in this model. In other words, if a healthy B cell population were included in the model, it would decouple from the other equations. While, in a healthy person, homeostatic mechanisms certainly play a role in keeping the B-CLL phenotype population very small, we are concerned here with situations in which the B-CLL cells have escaped these control mechanisms [18] . In equation (1), the term b B represents a constant source of B-CLL cells from another compartment, such as bone marrow. The term (r − d B )B represents the density dependent change of the leukemic population, that is, the net increase or decrease due to division and death of leukemic cells. Leukemic cell losses due to interactions with NK cells and effector T cells are represented by the terms d BN BN and d BT BT respectively. These terms assume mass action between B-CLL cells and NK and T cells, an assumption that is justified by our previous assumption that the cell populations are well mixed in the blood, so that direct interactions between cells occur at a rate proportional to their concentrations.
Natural Killer Cells (NK): We represent the NK dynamics in equation (2) . There is some evidence that although natural NK activity may be weak in B-CLL patients, there is a treatment possibility involving expanding NK cells from the peripheral blood of B-CLL patients, and further there is evidence that these cells have cytotoxic capacity [4, 6] . In general, NK cells recognize "non-self" cells, and eliminate them.
In this model, we assume NK cells are being produced at a constant rate, independent of the presence of B-CLL. We represent a constant source rate of NK cells with the term b N . The death rate, d N N, is proportional to the existing NK population. NK cells may become deactivated once they have interacted with B-CLL cells. Deactivation through contact with the B-CLL cells is represented through the mass action term d N B N B. As above, the mass action term is justified by our previous assumption of well-mixed cell populations.
Cytotoxic T Cell (CD8 + T): Equation (3) represents killer T cell dynamics in our model. We include killer T cells in this model since there is evidence that T cells have a therapeutic effect on B-CLL. This effect may additionally be enhanced through the use of tumor vaccine [8, 17] . T cell population growth is represented by b T , and natural death by d T T .
There is evidence that the cytolytic activity of specific T cells is mediated through the perforin-granzyme pathway [17] . Therefore, after a number of encounters, a T cell can no longer induce lysis due to lack of perforin. Furthermore, it has been noted experimentally that the leukemic clone produces large amounts of various immune suppressive factors [17] . In order to reflect this suppression of T-cell activity and gradual deactivation in the model, we include a deactivation term for the killer T cells, just as we do for the NK cells.
Deactivation + helper T population. The ability of B-CLL cells to stimulate the recruitment and activation of T cells through helper T cells will in general increase as the concentration of B-CLL cells in the system increases. However, T cell recruitment and activation is limited by an upper threshold. This recruitment action is assumed to occur in the lymph system where there may be disproportionately more B-CLL cells compared to CD4
+ helper T cells. Saturationlimited dynamics are commonly used when modeling immune cell recruitment, as in Moore and Li [11] and de Pillis et al. [19] .
Helper T Cells (CD4 + T): Equation (4) 
3. Parameters and data fitting. We used several sources in the literature to determine and cross-check parameter value ranges for our model. Although parameter values within a patient may not be static, for a given simulation we approximate the parameters by a fixed value, representing an average value over time for that particular parameter. Furthermore, parameter values will vary from patient to patient. Table 1 provides values for all the parameters in the model equations (1) - (4). Details about the sources and methods of estimation of these parameters have been included in comments 1 -16 of Appendix B. Table 2 provides ranges for biological values of the initial cell concentrations. Details about the sources and methods of estimation of these parameters have been included in comments 1 -3 of Appendix C .
The study of Messmer et al. [16] provides in vivo B-CLL proliferation and turnover data measured in a group of nineteen patients. We used these measurements to assign value ranges to our model parameters r and d B . The Messmer study additionally provides time series B-CLL data within each patient. The data Messmer et al. present are the number of B-CLL cells within each patient, over approximately a 200 to 250 day period, that are marked with deuterated water (2H2O -"heavy water"). This cell count represents a fraction of the entire B-CLL population within the patient. Messmer et al. also propose two simple mathematical models that track only cell birth and death dynamics. They compare their model simulations describing the dynamics of the marked B-CLL population to the measured patient data. For certain patients, good model fits to the data were not found. This is not surprising, since the model only tracks birth and death of cells, and does not account for any other cell dynamics, such as immune system interference. It is commendable that, using such a simple model, good model fits were found for many of the patients.
Our mathematical model incorporates immune system dynamics, in addition to B-CLL growth and death terms. For certain phenomena, such as tumor dormancy, immune system dynamics have been found to provide one explanation for the progression of cancers that might not otherwise be explained by birth and death cycles, or treatment interventions [21, 19] . We do not claim that the addition of the immune system is the only way to capture more complicated dynamics, but we do claim that immune system interactions provide one possible explanation for some observed patterns. Using the data from Messmer et al., we found that the presence of the immune system in our model does allow us to capture B-CLL progression patterns in certain patients that otherwise cannot be captured by a simpler model. However, our model equations represent dynamics of the entire B-CLL population, and not just a subset marked with heavy water. In order to calibrate our model outcomes to the patient data provided in this paper, we had to introduce an equation representing heavy water uptake.
Allowing H(t) to represent the fraction of heavy-water marked B-CLL cells, the change over time of the labeled cells population can be described by
H (t) = (fraction of new cells labeled) * (number new cells) − (cells dying off)
Translating this into mathematical terms, the following equation models the time dynamics of the fraction of heavy water marked B-CLL cells:
Note that H is a function of the entire B-CLL population B, but equations (1) -(4) do not depend on H. The H(t) population dynamics are different from those of the larger B-CLL population. Messmer et al. [16] administered heavy water to the nineteen patients for 84 days, and then measured marked B-CLL cells by using mass spectroscopy to count the fractions of leukemic cells that incorporated heavy water in their DNA before and after stopping heavy water intake. Once the heavy water infusion is stopped, no new H(t) cells are created, and this cell population begins to die off. Hence, while the birth and death parameters of the marked B-CLL population are the same as those for the larger B-CLL population, the H dynamics depend on the degree of cell labeling in newborn cells.
The function h(t) in equation (5) represents the percent of heavy water loading in the cells, and is given by the following equations: The parameter, f w is the fractional daily water exchange, and is patient specific. This parameter can be estimated, as described in [16] , from the patient's body weight and the prescribed heavy water protocol. Estimates for the data sets used in this paper are given in Table 3 . The derivation of the equation for h(t) can be found in [16] and, for completeness, in Appendix D. We carried out a least squares fit of equation (5), used in conjunction with our model equations (1) - (4), to patient data in Messmer et al. [16] . These results are displayed for 6 patients in Figures 1 and 2 .
The data for these six patients, represent a variety of disease progression patterns. These data sets were chosen to test our model's ability to reflect a range of disease dynamics. We present fits to patients 109, 331, 332, 355, 360 and 418 from the Messmer study. Of those data sets, the Messmer birth-death models were unable to obtain satisfactory fits to data from patients 109 and 418.
As can be seen in the lower panels of figures 1 and 2, we are able to obtain reasonable fits to all six sets of patient data with our model equations, including the data from patients 109 and 418. Other patient data sets, such as that for patient 360, were considered by Messmer et al. to have been reasonably well captured by their models. However, upon comparison between figure 2 in this paper, and figure 3 of Messmer et al., it can be seen that even in the case of patient 360, the addition of the immune component in our model allows for a closer prediction to the dynamics of the labeled B-CLL cells population. In particular, in patients 360 and 418, our heavy water equation fitted to the data predicts a sharp increase and subsequent decrease in the fraction of labeled cells, a dynamic that reflects the patient data well, but that is difficult to capture in the absence of immune system interactions.
The patient data provided in Messmer et al. [16] also give a means to obtaining additional model parameters that may not be available in the literature. The model parameters that can be obtained through fitting to the Messmer patient data are presented Table 3. 4. Results.
4.1.
Sensitivity and uncertainty analyses. In order to determine the effect of our estimates on model outcomes, a sensitivity analysis was performed on all parameters of the model. Ten thousand values were drawn for each parameter from a uniform distribution that was supported on the intervals specified in Table  1 . A Latin Hypercube sampling method was used to randomly select vectors of parameter-values to be used for each run. Details of the Latin Hypercube Sampling procedure can be found in the paper by Blower et al. [22] . The distribution of all cell counts after 1 month, 2 months and 8 months of simulation are shown in Figure  3 .
We note that, after eight months of simulation, all of the four cell populations are zero for most of the parameter values. The cytotoxic and helper T cells are either zero or at a very high level, while the B cells and NK cells cover a wider range of values. This observation leads us to conclude that, for the parameter ranges used, the disease has died out after 8 months in 82.4% of the cases (this is the number of simulations that result in a B-CLL count close to zero after 8 months). Furthermore, cytotoxic T cell levels remain high after 8 months only 5% of the time. From the distributions presented here, we are unable to say whether the high levels of T-cells persist when the B-CLL levels are high, but a further analysis (data not shown) reveals that B-CLL levels after 8 months are generally low in the 5% of the cases when both T cell and TH cell levels are high. Thus, there is a heterogeneity in the population whose disease is in remission: some have significant T cell activity while others do not. Cell Numbers Figure 3 . Distribution of the four cell types for the 10,000 parameter choices selected using the Latin Hypercube Sampling technique. In each of the sub-panels, the x-axis shows the number of cells and the y-axis shows the fraction of the 10,000 runs that resulted in the given cell number. The variability in cell number that is observed in the first month of simulation has largely disappeared after 8 months.
Partially ranked correlation coefficients (PRCC) and their associated p-values were calculated from these 10,000 simulations where ranked parameter values were correlated with the 8-month and 2-month levels of B-CLL and the three immune cell types: NK, T and TH cells. Only those parameters that were monotonically related to the outcomes were considered in the analysis. In Figure 4 we show those parameters that have an obvious correlation with the outcome, and whose PRCCs are significant at the .001 level. We show here the analyses at two months and 8 months because they show some variety in correlation to outcome, while clearly pointing out some significant parameters. We performed the same analysis at one month, but fewer parameters were found to be significantly related to outcomes. The PRCC values shown in Figure 4 are displayed in Table 4 .
The sensitivity analysis can help to identify model parameters that could be particularly important to the progression of the disease. The PRCC results shown in Figure 4 indicate that the parameter a T H has a strong positive correlation with N K, T and T H levels, and as noted earlier, a strong negative correlation with diseased B cell levels. These correlations persist through the first 8 months of simulation. The correlation is not surprising, since a T H represents the strength of the T cell recruitment. Furthermore, the parameter a T H varies from patient to patient, as can be seen in Table 3. 4.2. Bifurcation analysis. We can gain a great deal of qualitative information about disease progression by studying the long term behavior of the system of ordinary differential equations that describes the model. For example, if the system has stable equilibria, or steady states, then the system may move towards one of these steady states if it is initially in the basin of attraction of a stable equilibrium. The first step in such a stability analysis involves finding the equilibria of the system, typically using numerical methods. Local stability can then be determined by linearizing the system near the equilibria, and then by determining the stability of the linearized system. Often, the location and stability of these equilibria depends on the values of the parameters: determining this dependence can give further insight into the role of a parameter on the disease outcome. A bifurcation analysis involves determining the location and stability of equilibria for a range of parameter values, and then identifying parameter values at which a qualitative change in system behavior occurs.
We have automated this process using Matlab. For each parameter value, we use a numerical root-finding routine to find equilibria, by finding the roots of the right-hand side of the system of ODEs. We then numerically find the eigenvalues of the Jacobian of the system, evaluated at biologically relevant equilibria (i.e. those that are non-negative) in order to determine the stability of the equilibria. We can plot the results as a function of the parameter value to locate any bifurcations, such as parameter values at which an equilibria changes stability, or at which equilibria appear or disappear.
Since the parameter measuring the strength of the adaptive immune response, was found to have the most effect on both the short and long term evolution of the system, we performed a bifurcation analysis with respect to the parameter a T H . Since this is a fairly standard procedure, we omit the details, and just give the results. The analysis, depicted in the top panel of Figure 5 shows that a saddle node bifurcation occurs at a T H ≈ 8. , the behavior of the B cell population is determined by the initial conditions. The trajectories in the lower two panels of Figure 5 illustrate these dynamics.
We note that other parameters shown to be significant in the sensitivity analysis, such as d T H and d BT give rise to similar bifurcation scenarios. While we do not reproduce the diagrams here since they are qualitatively similar to the one shown, any therapy that manipulates these parameters would motivate a careful study, using Center: Solutions with B 0 = 80c/µL, and B 0 = 140c/µL converge to the stable equilibrium while B 0 = 180c/µL yields an increasing solution that moves away from the unstable equilibrium at B E1 = 172.2. Note that the trajectory starting at B 0 = 80c/µL first rises above the stable equilibrium at B E2 = 97.4 , and then decreases towards it. Bottom: With B 0 = 140 and a T H < 8.186 × 10 −6 , B cell concentrations grow without bound, while increasing a T H above 8.186 × 10 −6 results in a stable B cell concentration. Other parameters are given in Appendix E. the same techniques described above, to determine critical values of the parameters and approximate basins of attraction. Indeed, a careful study of all parameters in the model might uncover other types of bifurcations and other limiting behavior such as limit cycles or other types of attractors. We leave this for future work.
In this model it is clear that the NK and T components of the immune system keep B-CLL growth under control. Figure 6 shows a simulation in which the disease level approaches a low stable equilibrium. That is, the B-CLL population rises to approximately 100 cells per µliter and remains there for some time (till day 2000 in our simulations). This could correspond to a patient with undetected low level illness. For this hypothetical patient, we simulate a compromised immune system by setting d BN = 0 and d BT = 0 on day 2000 in our model. As a result, the B-CLL cell population begins to grow rapidly, as shown in the right half of Figure 6 .
Our good qualitative fits to several patients' data sets demonstrates that this model can be implemented across a range of disease behavior and in patient specific settings.
Conclusion and future directions.
We have created a model for B-CLL disease dynamics that is better able to reflect clinical data than are other existing models as of this writing. Since the NK and T immune cell populations are understood to play an important role in B-CLL progression, we believe the model improvements stem from the incorporation of these cell populations in the model.
The addition of the different immune populations makes it possible to capture a wide range of disease progression dynamics. For example, the B-CLL populations in the six patients we have presented show qualitatively different time dynamics: The increase in B-CLL over the first 84 days of heavy water administration can follow either a convex or a concave increasing curve, and B-CLL decline after day 84 can be steep, moderate, or almost level. All of these qualitatively different forms are captured by our model.
The sensitivity analysis we performed revealed which parameter values were more strongly correlated to disease progression than others. For some of these parameters, such as those representing tumor birth and death rates, assays exist that can give patient-specific values for these parameters, potentially improving patient prognosis. One parameter value, the immune cell recruitment rate, was found to be significant, but it is not a value that is easily measured in vivo. This parameter may be a good target for new assay development.
Bifurcation analyses similar to that shown in Section 4.2 can be performed for other significant parameters in the model. This can help identify critical values of parameters that could potentially be measured in the clinic. Treatments that drive parameter values into regions where a relatively small B-cell level is stable would be indicated in order to slow disease progression. We remark that the values of a T H fitted to the 6 data sets shown in Table 3 all fall well above the saddle-node bifurcation point. It is worth noting that this bifurcation point can shift when other model parameters are changed. With an eye towards personalized medicine, we might envision these diagrams tailored to parameters measured in the clinic, and used to design the most efficient interventions.
We have shown that the immune system plays an important role in the progression of B-CLL observed in the clinic. Useful future model extensions would Table 3 . Other parameters as in Table 1 .
incorporate B-CLL treatments, ideally including both chemotherapy and immunemodulating treatments. The compartmentalized form of the model we have presented, which separates out NK, T and helper-T cell dynamics, provides a useful starting point to modeling treatments that target these specific populations.
Appendix A. Tables. (steady state values) and this puts us into acceptable biological range of T cells. There is some evidence that T cell counts in B-CLL patients may be higher in healthy patients, and in fact some of the Messmer et al. [16] patients have highly variable B-CLL counts as a fraction of WBCs. 3. If total lymphocyte count in sick B-CLL patients is 12 × 10 3 to 300 × 10 3 cells per µliter, [6, 27, 29] and if the CD4 + T cell count is 50-60% of lymphocytes, [26] then the CD4 + range is 6 × 10 3 − 180 × 10 3 cells per µliter.
Appendix D. Derivation of h(t). The function h(t), representing the percent of heavy water loading in the B-CLL cells, is derived as follows. (This derivation is also in [16] .) The change in h over time can be described by the ordinary differential equation
where f w is the fraction of daily water exchange: f w = Daily water turnover rate Total water in body .
In the protocol used to gather the data in Messmer et al. [16] , h in = 3 % from day 0 to day 5, h in = 1 % from day 5 to day 84, and h in = 0 percent from day 84 on.
We can solve the ODE describing h(t) through separation of variables. Assuming the initial value of h is 0, that is, h(0) = 0, we have 1
This yields: h(t) = .03 1 − e −fwt , 0 ≤ t ≤ 5, and at day 5, h(5) = .03(1 − e −5fw ) = h 5 .
To find h for the next time range, we then solve for h(t) for 5 ≤ t ≤ 84, and set h in = .01. We use the initial condition h 5 from above. This gives: h(t) = .01 + (h 5 − .01)e fw(5−t) , 5 ≤ t ≤ 84.
At day 84, we then see that h(84) = h 84 = .01 + (h 5 − .01)e −79fw . Since h in = 0 for t > 84 (the "washout" phase), the ODE describing h becomes h = −f w h, the solution of which is h(t) = h 84 e −fw(t−84) .
In summary, h(t) is given by: 
